Clomipramine HCl Capsules by Lupin approved by FDA
27 November 2018 | News
It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD)
Pharma company, Lupin has announced that it has received approval for its Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg from the United States Food and Drug Administration (FDA) to market a generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg.
Lupin’s Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg.
It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
Anafranil Capsules, 25 mg, 50 mg, and 75 mg had annual sales of approximately USD 109.6 million in the US (IQVIA MAT September 2018).
